Table 2.

Baseline characteristics of SAVR and TAVR patients during the TAVR era

Variable	SAVR	TAVR	P-value
N	545 (79.4%)	141 (20.6%)
Demographics
Age	74 (64, 82)	82 (77, 86)	< 0.001
Female	209 (38.3%)	62 (44.0%)	0.262
Race/Ethnicity			0.248
White	483 (88.6%)	132 (93.6%)
Black	54 (9.9%)	8 (5.7%)
Other	8 (1.5%)	1 (0.7%)
BSA	2 (1.8, 2.1)	1.9 (1.7, 2.1)	0.163
Comorbidities
EF	50 (50, 50)	55 (46.2, 55)	0.451
Creatinine	1 (0.8, 1.2)	1.2 (1, 1.4)	0.4
History of Smoking	93 (17.2%)	40 (28.4%)	0.004
CVD	63 (11.6%)	28 (19.9%)	0.014
PVD	33 (6.1%)	35 (24.8%)	< 0.001
COPD	37 (6.8%)	48 (34%)	< 0.001
Diabetes	165 (30.3%)	60 (42.6%)	0.008
Hypertension	439 (80.6%)	122 (86.5%)	0.130
AS	493 (90.8%)	126 (98.4%)	0.002
AR (≥ moderate)	99 (18.2%)	15 (11.0%)	0.062
MR (≥ moderate)	31 (5.7%)	14 (10.3%)	0.082
CHF (NYHA class I-III)	503 (92.3%)	120 (85.1%)	0.013
CHF (NYHA class IV)	40 (7.3%)	16 (11.8%)	0.132
Previous sternotomy	115 (21.1%)	68 (48.9%)	< 0.001
STS-PROM, mean (SD)	3.8% (2.8%)	9.3% (5.3%)	< 0.001
STS-PROM <12%	535 (98.2%)	87 (79.1%)	<0.001
Reason for not getting SAVR among those with STS PROM<12%
Frailty	NA	45 (51.7%)
Severe pulmonary disease	NA	10 (11.5%)
Cirrhosis	NA	2 (2.3%)
Redo TAVR	NA	3 (3.4%)
Porcelain aorta	NA	18 (20.7%)
Hostile mediastinum	NA	9 (10.3%)
Outcomes
30-day mortality	8 (1.5%)	4 (2.8%)	0.281

Categorical data represented as frequency (%). Continuous data represented as median (IQR –interquartile range). Abbreviations as follows: SAVR –surgical aortic valve replacement, TAVR –transcatheter aortic valve replacement, BSA –body surface area, EF –ejection fraction, CVD –cerebrovascular disease, PVD –peripheral vascular disease, COPD –chronic obstructive pulmonary disease, AS –aortic stenosis, AR –aortic regurgitation, MS –mitral stenosis, MR –mitral regurgitation, TR –tricuspid regurgitation, MI –myocardial infarction, CHF –congestive heart failure, NYHA –New York Heart Association. AS was defined as any degree of stenosis.